Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

17P - Engineering and expression of constitutive activators of the PD-1 and LAG-3 signaling pathways

Date

17 Sep 2020

Session

E-Poster Display

Topics

Basic Science

Tumour Site

Presenters

Luisa Chocarro

Citation

Annals of Oncology (2020) 31 (suppl_4): S245-S259. 10.1016/annonc/annonc265

Authors

L. Chocarro1, M.J. García Granda1, M. Zuazo1, H. Arasanz2, A. Bocanegra1, E. Blanco1, C. Hernández Sáez1, G. Fernández Hinojal2, R. Vera2, G. Kochan1, D. Escors1

Author affiliations

  • 1 Oncoimmunology Research Unit, Navarrabiomed, Instituto de Investigaciones Sanitarias de Navarra (IdISNA), UPNA, 31008 - Pamplona/ES
  • 2 Department Of Medical Oncology, Complejo Hospitalario de Navarra, Instituto de Investigaciones Sanitarias de Navarra (IdISNA), 31008 - Pamplona/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 17P

Background

The lack of PD-1 or LAG-3 mutants with constitutive inhibitory activities prevents a systematic approach to dissect all the intracellular events regulated by PD-1 and LAG-3 that establish a strong T cell dysfunctionality in patients with intrinsic resistance to PD-1 therapies (Zuazo et al., 2019). It is thought that PD-1 and LAG-3 form a supramolecular complex together with TCR components in order to exert their inhibitory activity over TCR signal transduction. So far, no PD-1 and LAG-3 mutants with constitutive signalling activities have been described. Here we have constructed molecules that provide an initial TCR-dependent signal in T cells that lead to a sustained inhibitory activity of PD-1 and LAG-3.

Methods

To construct molecules with constitutive PD-1 and LAG-3 signaling activities in T cells, we replaced their immunoglobulin domains with a sequence encoding a single chain antibody that binds CD3. In addition, the coding sequence for GFP and mCherry were introduced at their c-terminus to track their expression in T cells. These fusion genes were cloned into the pDUAL lentivector expression system, which co-express antibiotic resistance for selection of cells lines. When expressed in T cells, the engagement with CD3 will trigger a TCR signal in neighbouring T cells, and these molecules will then transmit either PD-1 or LAG-3 signals. To test their expression, human T cells were transduced with lentivectors expressing these constructs singly or in combination, selected with antibiotics and visualized in living cells by fluorescence microscopy.

Results

Both constructs showed strong expression levels, with high accumulation especially at focal points of cell-to-cell contacts as would be expected for CD3-binding molecules. Similar expression patterns were observed in primary human T cells after lentivector modification. The growth of Jurkat cell lines expressing these molecules was evidently delayed compared to control untransduced T cells and to T cells constitutively expressing just the CD3-activating construct.

Conclusions

These results showed that these molecules had functional PD-1 and LAG-3 signaling in T cells leading to reduced cell growth. This will allow to study the reasons behind the intrinsic resistance to PD-1 blockade.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

OncoImmunology Research Unit, Navarrabiomed, Instituto de Investigaciones Sanitarias de Navarra (IdISNA), UPNA.

Funding

This research was supported by Asociación Española Contra el Cáncer (AECC, PROYE16001ESCO); Instituto de Salud Carlos III, Spain (FIS project grant PI17/02119); Gobierno de Navarra Biomedicine Project grant (BMED 050-2019); TRANSPOCART (Instituto de Salud Carlos III); “Precipita” Crowdfunding grant (FECYT); Crowdfunding grant from Sociedad Española de Inmunología (SEI); DESCARTHES project grant (Industry department, Government of Navarre).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.